ERBB2 and gastric cancer: In the Trastuzumab for Gastric Cancer (ToGA) trial, the overall HER2 amplification or overexpression was 22.1%, and otherwise highest in patients with intestinal histology (31.8%) and the lowest in those with diffuse histology (6.1%), while it was higher in adenocarcinomas located in the GEJ compared to those from the gastric region (32.2% vs. 21.4%, respectively) [111].